首页|siRNA药物在肿瘤靶向治疗中的研究进展

siRNA药物在肿瘤靶向治疗中的研究进展

扫码查看
小干扰RNA(siRNA)是一种新型核酸药物,其通过RNA干扰(RNAi)机制,在转录后水平靶向沉默靶基因的表达,从而发挥治疗疾病的作用.siRNA作为一种精准、特异、高效的基因沉默疗法,在肿瘤靶向治疗领域备受瞩目.目前,已有多款抗肿瘤siRNA疗法进入临床试验阶段.综述了近年来siRNA在肿瘤靶向治疗中的研究进展,包括siRNA作用机制、抗肿瘤siRNA药物研发近况,以及siRNA药物体内递送的优化策略,旨在为抗肿瘤siRNA药物的研发与临床应用提供新思路.
Research Progress of siRNA Drugs in Tumor-targeted Therapy
Small interfering RNA(siRNA)is a new type of nucleic acid drug that plays its therapeutic roles through the RNA interference(RNAi)mechanism to target and silence the expression of target genes at the post-transcriptional level.As a precise,specific and efficient gene silencing therapy,siRNA has attracted much attention in the field of tumor-targeted therapy.Currently,several anti-tumor siRNA therapies have entered the clinical trial stage.This article summarizes the research progress of siRNA in tumor-targeted therapy in recent years,including the mechanism of action for siRNA,the recent development of anti-tumor siRNA drugs,and the optimization strategies for the in vivo delivery of siRNA drugs,aiming to provide new insights for the development and clinical application of anti-tumor siRNA drugs.

RNA interferencesmall interfering RNAtumor-targeted therapyextra-hepatic targetingnanocarrier

张从一、牧原、李振海、王欣月、蔡文秋、刘晓婧、邹倩、李梦玮

展开 >

中国药科大学生命科学与技术学院,江苏 南京 210009

RNA干扰 小干扰RNA 肿瘤靶向治疗 肝外靶向 纳米载体

国家自然科学基金江苏省自然科学基金

82103118BK20210418

2024

药学进展
中国药科大学

药学进展

影响因子:0.624
ISSN:1001-5094
年,卷(期):2024.48(7)
  • 3